5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results
Title:
5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results
Author:
Seymour, John F. Roberts, Andrew W. Carney, Dennis A. Dyer, Martin J.S. Kipps, Thomas J. Hallek, Michael Bociek, R. Gregory Brown, Jennifer R. Wierda, William G. Rai, Kanti Ribeiro de Oliveira, Moacyr McKeegan, Evelyn Chyla, Brenda Busman, Todd Krivoshik, Andrew Enschede, Sari Humerickhouse, Rod